Lee's Pharma从Alexza获取Staccato吸入技术,获得IP、设施和管道资产,用于CNS药物开发。 Lee's Pharma acquires Staccato inhalation tech from Alexza, gaining IP, facility, and pipeline assets for CNS drug development.

Lee的制药控股有限公司已经从Alexza制药公司购买了Staccato One Breath Technology平台和相关资产,预计到2025年底关闭。 Lee's Pharmaceutical Holdings Limited has acquired the Staccato One Breath Technology platform and related assets from Alexza Pharmaceuticals, expected to close by year-end 2025. 该协议授予吸入技术的全部所有权,包括知识产权、加利福尼亚州弗里蒙特的一个GMP设施,以及开发和制造基于Staccato的药物的权利。 The deal grants full ownership of the inhalation technology, including intellectual property, a GMP facility in Fremont, California, and rights to develop and manufacture Staccato-based drugs. 它加强了Lee制药公司在中神经系统和神经退化性紊乱治疗方面的能力,消除了未来的许可证支付,并整合了用于帕金森病和循环呕吐综合症的2阶段2输油管资产。 It strengthens Lee's Pharm’s capabilities in central nervous system and neurodegenerative disorder treatments, eliminates future licensing payments, and integrates two Phase 2 pipeline assets for Parkinson’s disease and cyclic vomiting syndrome. 该公司还根据与UCB签订的一项全球协议获得权利,向目前处于第三阶段试验阶段的Stacato alprazolam公司提供6 050万美元的里程碑付款、分层使用费和制造业收入。 The company also gains rights under a global agreement with UCB to supply Staccato alprazolam, currently in Phase 3 trials, with potential for up to $60.5 million in milestone payments, tiered royalties, and manufacturing revenue.